Compare ONTF & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONTF | SGHT |
|---|---|---|
| Founded | 1998 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 338.0M | 395.5M |
| IPO Year | 2021 | 2021 |
| Metric | ONTF | SGHT |
|---|---|---|
| Price | $7.98 | $6.06 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 8 |
| Target Price | $7.40 | ★ $8.23 |
| AVG Volume (30 Days) | ★ 530.8K | 352.0K |
| Earning Date | 02-24-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $141,348,000.00 | $76,052,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.07 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.35 | $2.03 |
| 52 Week High | $8.10 | $9.24 |
| Indicator | ONTF | SGHT |
|---|---|---|
| Relative Strength Index (RSI) | 78.90 | 31.33 |
| Support Level | $7.95 | $5.96 |
| Resistance Level | $8.07 | $6.72 |
| Average True Range (ATR) | 0.04 | 0.46 |
| MACD | -0.05 | -0.16 |
| Stochastic Oscillator | 20.83 | 4.01 |
ON24 Inc provides a cloud-based intelligent engagement platform that combines experiences with personalization and content, to enable sales and marketing organizations to capture and act on connected insights at scale. The Company's platform offers a portfolio of interactive and hyper-personalized digital experience products that create and capture actionable, real-time data at scale from millions of professionals to provide businesses with buying signals and behavioral insights to efficiently convert prospects into customers. It provides solutions to Financial services, Life Sciences, Life sciences, Insurance, Technology, Associations, and Others.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.